Source 1primary paper2025MED
Toolkit/chimeric antigen receptor T cells
chimeric antigen receptor T cells
Also known as: CAR-T, CAR-T cells, CAR-T cell therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Key ACT modalities include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), and T cell receptor (TCR)-engineered T cells.
Usefulness & Problems
Why this is useful
CAR-T cells are included in the review as a T cell-inspired therapeutic delivery and cell therapy modality. The abstract places them within a broader comparison of T cell-based delivery systems.; targeted therapeutic delivery; cancer therapy; CAR-T cells are described as a cell-based immunotherapy modality discussed for AML. The review frames them as one of the main engineered therapeutic approaches in the field.; AML immunotherapy; CAR-T cell therapy is presented as an adoptive cell therapy modality that uses genetically engineered immune cells to bolster anti-tumor immune responses. The review focuses on its application to colorectal cancer.; adoptive cell therapy for colorectal cancer; bolstering anti-tumor immune responses
Source:
CAR-T cells are included in the review as a T cell-inspired therapeutic delivery and cell therapy modality. The abstract places them within a broader comparison of T cell-based delivery systems.
Source:
targeted therapeutic delivery
Source:
cancer therapy
Source:
CAR-T cells are described as a cell-based immunotherapy modality discussed for AML. The review frames them as one of the main engineered therapeutic approaches in the field.
Source:
AML immunotherapy
Source:
CAR-T cell therapy is presented as an adoptive cell therapy modality that uses genetically engineered immune cells to bolster anti-tumor immune responses. The review focuses on its application to colorectal cancer.
Source:
adoptive cell therapy for colorectal cancer
Source:
bolstering anti-tumor immune responses
Problem solved
The abstract presents CAR-T cells as part of a T cell-based strategy to improve targeted therapeutic outcomes.; enables T cell-based targeted therapy and delivery; They aim to improve immunotherapeutic outcomes in AML through targeted cellular therapy.; providing a cell-based immunotherapy modality for AML; It aims to improve anti-tumor immune responses where current standard colorectal cancer treatments have limited efficacy, especially in advanced and metastatic disease.; providing a genetically engineered immune-cell approach for anti-tumor therapy
Source:
The abstract presents CAR-T cells as part of a T cell-based strategy to improve targeted therapeutic outcomes.
Source:
enables T cell-based targeted therapy and delivery
Source:
They aim to improve immunotherapeutic outcomes in AML through targeted cellular therapy.
Source:
providing a cell-based immunotherapy modality for AML
Source:
It aims to improve anti-tumor immune responses where current standard colorectal cancer treatments have limited efficacy, especially in advanced and metastatic disease.
Source:
providing a genetically engineered immune-cell approach for anti-tumor therapy
Problem links
enables T cell-based targeted therapy and delivery
LiteratureThe abstract presents CAR-T cells as part of a T cell-based strategy to improve targeted therapeutic outcomes.
Source:
The abstract presents CAR-T cells as part of a T cell-based strategy to improve targeted therapeutic outcomes.
providing a cell-based immunotherapy modality for AML
LiteratureThey aim to improve immunotherapeutic outcomes in AML through targeted cellular therapy.
Source:
They aim to improve immunotherapeutic outcomes in AML through targeted cellular therapy.
providing a genetically engineered immune-cell approach for anti-tumor therapy
LiteratureIt aims to improve anti-tumor immune responses where current standard colorectal cancer treatments have limited efficacy, especially in advanced and metastatic disease.
Source:
It aims to improve anti-tumor immune responses where current standard colorectal cancer treatments have limited efficacy, especially in advanced and metastatic disease.
Published Workflows
Objective: Engineer a modular SNIPR-based receptor platform that senses soluble ligands and activates customized cellular functions for therapeutic control and synthetic cell-cell communication.
Why it works: The abstract states that the adapted SNIPR platform can be activated by natural and synthetic soluble factors through an endocytic, pH-dependent cleavage mechanism, enabling soluble-cue sensing to drive bespoke cellular outputs.
endocytic activationpH-dependent cleavagereceptor architecture adaptationcell engineering
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
targeted cellular delivery/transportTechniques
Structural CharacterizationTarget processes
editingInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
This modality requires engineered CAR-T cells, but the abstract does not provide details on receptor design, manufacturing, or administration.; requires CAR-T cell engineering; efficacy may require structural optimization of CAR constructs; efficacy may require functional enhancement of CAR-T cells; The abstract states that ACT involves in vitro expansion or genetic engineering of immune cells. For CAR-T specifically, this implies engineered immune-cell preparation before use.; requires in vitro expansion or genetic engineering of immune cells
The abstract does not specify which limitations of CAR-T-based delivery remain unresolved.; current limitations are mentioned but not detailed in the abstract; The abstract states that AML immunotherapy remains limited by early relapse and treatment-associated toxicities, indicating current CAR-T approaches do not fully overcome these barriers.; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; The abstract states that CAR-T therapy still faces major barriers in solid tumors such as colorectal cancer, including antigen heterogeneity, immunosuppressive tumor microenvironment, and on-target off-tumor toxicity.; faces significant challenges in solid tumors like colorectal cancer; antigen heterogeneity; immunosuppressive tumor microenvironment; on-target off-tumor toxicity
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Source 3primary paper2026MED
Ranked Claims
Using T cells as delivery vehicles enables prolonged circulation time, targeted drug transport, and reduced toxicity to cells and tissues.
Utilizing T cells as delivery vehicles enables prolonged circulation time and targeted drug transport, along with reduced toxicity to cells and tissues.
T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and CAR-T cells exhibit biocompatibility, biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers.
T cell-inspired approaches-including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and chimeric antigen receptor (CAR)-T cells-exhibit remarkable properties such as inherent biocompatibility and biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers.
CAR-T cell therapy has shown success in hematological malignancies but faces significant challenges in solid tumors such as colorectal cancer.
The explored improvement strategies aim to enhance CAR-T cell specificity, improve resistance to immunosuppressive signals, and optimize in vivo functionality.
Major challenges for CAR-T therapy in colorectal cancer include antigen heterogeneity, an immunosuppressive tumor microenvironment, and on-target off-tumor toxicity.
Chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, and T cell receptor-engineered T cells are key adoptive cell therapy modalities in colorectal cancer discussion.
Therapeutic modalities discussed for AML immunotherapy include immunoconjugates, bispecific T-cell engagers, and CAR-T cells.
Proposed strategies to enhance AML immunotherapy efficacy include combination therapies, structural optimization of CAR constructs, functional enhancement of CAR-T cells, identification of novel targets, and development of next-generation cellular therapies.
Combinatorial approaches including immune checkpoint inhibitors, cytokines, and CRISPR/Cas9 are being explored to address CAR-T limitations in colorectal cancer.
Approval Evidence
3 sources9 linked approval claimsfirst-pass slug chimeric-antigen-receptor-t-cells
T cell-inspired approaches-including ... chimeric antigen receptor (CAR)-T cells
Source:
Key ACT modalities include chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TILs), and T cell receptor (TCR)-engineered T cells.
Source:
Therapeutic modalities discussed include immunoconjugates, bispecific T-cell engagers and chimeric antigen receptor T (CAR-T) cells.
Source:
functional benefitsupports
Using T cells as delivery vehicles enables prolonged circulation time, targeted drug transport, and reduced toxicity to cells and tissues.
Utilizing T cells as delivery vehicles enables prolonged circulation time and targeted drug transport, along with reduced toxicity to cells and tissues.
Source:
property assertionsupports
T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and CAR-T cells exhibit biocompatibility, biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers.
T cell-inspired approaches-including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and chimeric antigen receptor (CAR)-T cells-exhibit remarkable properties such as inherent biocompatibility and biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers.
Source:
challenge statementsupports
CAR-T cell therapy has shown success in hematological malignancies but faces significant challenges in solid tumors such as colorectal cancer.
Source:
engineering goalsupports
The explored improvement strategies aim to enhance CAR-T cell specificity, improve resistance to immunosuppressive signals, and optimize in vivo functionality.
Source:
limitation statementsupports
Major challenges for CAR-T therapy in colorectal cancer include antigen heterogeneity, an immunosuppressive tumor microenvironment, and on-target off-tumor toxicity.
Source:
modality membershipsupports
Chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, and T cell receptor-engineered T cells are key adoptive cell therapy modalities in colorectal cancer discussion.
Source:
modality scopesupports
Therapeutic modalities discussed for AML immunotherapy include immunoconjugates, bispecific T-cell engagers, and CAR-T cells.
Source:
strategysupports
Proposed strategies to enhance AML immunotherapy efficacy include combination therapies, structural optimization of CAR constructs, functional enhancement of CAR-T cells, identification of novel targets, and development of next-generation cellular therapies.
Source:
strategy statementsupports
Combinatorial approaches including immune checkpoint inhibitors, cytokines, and CRISPR/Cas9 are being explored to address CAR-T limitations in colorectal cancer.
Source:
Comparisons
Source-stated alternatives
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.; The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Source:
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Source-backed strengths
inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers; presented as a major therapeutic modality in AML immunotherapy; has shown success in hematological malignancies
Source:
inherent biocompatibility and biodegradability
Source:
prolonged circulation lifespan
Source:
ability to traverse biological barriers
Source:
presented as a major therapeutic modality in AML immunotherapy
Source:
has shown success in hematological malignancies
Compared with CAR-T
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with CAR-T cells
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with CAR-T cell therapy
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with CAR-T therapy
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with Chimeric antigen receptor T-cell therapy
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.; The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The review compares CAR-T cells with conventional nanomedicine and other T cell-inspired delivery approaches.
Source:
The abstract contrasts CAR-T cells with immunoconjugates and bispecific T-cell engagers as other AML immunotherapy modalities.
Compared with CRISPR/Cas9
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Compared with CRISPR/Cas9 system
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Compared with TIL
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Shared frame: source-stated alternative in extracted literature
Strengths here: inherent biocompatibility and biodegradability; prolonged circulation lifespan; ability to traverse biological barriers.
Relative tradeoffs: current limitations are mentioned but not detailed in the abstract; clinical efficacy in AML remains limited by early relapse and treatment-associated toxicities; faces significant challenges in solid tumors like colorectal cancer.
Source:
The abstract names tumor-infiltrating lymphocytes and TCR-engineered T cells as other ACT modalities. It also mentions combinatorial approaches with immune checkpoint inhibitors, cytokines, and CRISPR/Cas9-based editing.
Ranked Citations
- 1.
- 2.
- 3.